Asthma Medication Names: Inhalers, Biologics, and Stems

Asthma medications fall into a handful of core categories, and learning the names within each group is simpler than it first appears because drug names follow patterns that reveal what a medication does. The short-acting rescue inhaler most people recognize, salbutamol (called albuterol in the United States), sits alongside a sprawling cast of daily controllers, long-acting bronchodilators, leukotriene modifiers, and newer biologic injections. Each class has its own naming logic, its own brand-name confusion, and its own role in keeping airways open. Sorting through those names matters more than you might expect: research shows that patients who can’t correctly name their inhalers end up in the emergency department more often than those who can.

Rescue Inhalers and Short-Acting Beta-Agonists

The medication most people encounter first is a short-acting beta-agonist, usually abbreviated SABA. Salbutamol is the dominant rescue treatment for asthma worldwide, used both in the familiar handheld “blue inhaler” and in hospital nebulizers. In the United States, the same molecule goes by the name albuterol, which leads to immediate confusion for anyone reading international health information. They are the same drug. Terbutaline is the other SABA still in wide use, and it works through the same basic mechanism: relaxing the smooth muscle around the airways within minutes of inhalation.1Wiley Online Library (Pharmacology Research & Perspectives). A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra‐Long‐Acting β2‐Agonists Used for Asthma and COPD

Brand names for salbutamol and albuterol multiply the confusion. You may see Ventolin, ProAir, or Proventil on the label in North America. In other countries, Airomir and Salamol are common. These are all the same active drug delivered in slightly different inhaler devices. Terbutaline is typically sold as Bricanyl. The key takeaway is that the brand name on the canister tells you who manufactured the inhaler, not what drug class it belongs to. The generic name is the reliable identifier.

Inhaled Corticosteroids, the Daily Controllers

If SABAs are the fire extinguisher, inhaled corticosteroids (ICS) are the fire-prevention system. They reduce the underlying airway inflammation that causes asthma symptoms and are meant to be used every day, whether or not you feel symptoms. The most widely prescribed ICS names include:

  • Beclometasone: one of the earliest ICS drugs, sold as Qvar or Clenil.
  • Budesonide: sold as Pulmicort, also used in combination inhalers.
  • Fluticasone: available in two forms, fluticasone propionate (in Flovent and Flixotide) and fluticasone furoate (in Arnuity Ellipta).
  • Mometasone: sold as Asmanex.
  • Ciclesonide: sold as Alvesco, a newer option sometimes chosen because more of the drug activates inside the lungs rather than in the mouth and throat.

Notice that most ICS generic names end in “-sone” or “-sonide.” That suffix is a useful clue: when you see it on a prescription label, you’re almost certainly looking at a corticosteroid. Corticosteroids are the most effective treatment for the eosinophilic airway inflammation that drives most asthma, and combination inhalers pairing a corticosteroid with a long-acting bronchodilator have become the mainstay of therapy.2PubMed. Asthma therapy over 100 years

Long-Acting Bronchodilators

When a daily inhaled corticosteroid alone isn’t controlling symptoms well enough, a second medication is usually added. The two main classes are long-acting beta-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), and each has its own roster of names.

Common LABA generic names include salmeterol, formoterol, vilanterol, and indacaterol. Salmeterol and formoterol have been workhorses for decades, while vilanterol is a newer ultra-long-acting molecule designed for once-daily dosing. Formoterol has an additional distinction: it kicks in fast enough to double as a reliever, which is why it appears in the newer “anti-inflammatory reliever” strategy where patients use a combination ICS/formoterol inhaler for both daily maintenance and rescue.3PubMed. Asthma therapy over 100 years

On the LAMA side, tiotropium is currently the only long-acting muscarinic antagonist approved for asthma (it’s sold as Spiriva Respimat for asthma use). It works differently from beta-agonists, blocking the nerve signals that tighten airway muscles rather than directly relaxing the muscle itself. All three add-on classes, LABAs, LAMAs, and leukotriene receptor antagonists, have been shown to improve lung function and reduce flare-ups with safety profiles similar to placebo.4Nature Publishing Group. Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management

Combination Inhalers and Their Double-Barreled Names

Many people with asthma use a single inhaler that contains two or even three drugs at once. These combination inhalers are among the most commonly prescribed asthma products, and their names can be bewildering because you’re dealing with the brand name of the device, plus two or three generic drug names inside it. The most widely used combinations pair an ICS with a LABA:

  • Fluticasone propionate + salmeterol: sold as Advair (Diskus or HFA) in the U.S. and Seretide elsewhere.
  • Budesonide + formoterol: sold as Symbicort. This is the combination used in the maintenance-and-reliever approach because formoterol acts quickly.
  • Fluticasone furoate + vilanterol: sold as Breo Ellipta (or Relvar Ellipta outside the U.S.), a once-daily option.
  • Mometasone + formoterol: sold as Dulera (or Flutiform in some markets uses fluticasone + formoterol).

Triple-therapy inhalers, which add a LAMA to an ICS/LABA pair, are primarily used for COPD but are increasingly seen in severe asthma. Names like Trelegy Ellipta (fluticasone furoate + umeclidinium + vilanterol) are entering asthma conversations as well. The practical challenge for patients is remembering which inhaler is the daily controller and which is for emergencies, especially when the brand name doesn’t hint at the contents.

Leukotriene Modifiers and What the “-Ast” Ending Means

Montelukast, sold as Singulair, is the best-known leukotriene receptor antagonist (LTRA). It comes as a tablet rather than an inhaler and works by blocking leukotrienes, inflammatory chemicals that narrow the airways. Zafirlukast (Accolate) is another LTRA, though it has been discontinued in some markets.5Nature Publishing Group. Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management

The names of these drugs actually encode information about how they work. International drug-naming conventions use “stems” to signal a medication’s class. The stem “-ast” marks drugs used for asthma, and the sub-stem “-lukast” specifically identifies leukotriene receptor antagonists. So when you see a generic name ending in “-lukast,” you know it blocks leukotrienes, and you can predict it has a similar mechanism to montelukast.6PLoS ONE. Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names A third drug in this space, zileuton (Zyflo), works slightly differently: it blocks the enzyme that makes leukotrienes in the first place, rather than blocking their receptor. Its name doesn’t end in “-lukast” because the mechanism is distinct, even though it lands in the same general family of leukotriene modifiers.

Biologic Therapies and the “-Mab” Suffix

For people with moderate-to-severe asthma that doesn’t respond well to inhalers and oral medications, biologic therapies represent a newer frontier. These are monoclonal antibodies, lab-engineered proteins designed to block specific molecules in the inflammatory cascade. Their generic names all end in “-mab” (short for monoclonal antibody), and a preceding syllable hints at the target:

  • Omalizumab (Xolair): targets immunoglobulin E (IgE), the antibody that triggers allergic reactions. It was the first biologic approved for asthma.
  • Mepolizumab (Nucala): targets interleukin-5, a key driver of eosinophilic inflammation.
  • Benralizumab (Fasenra): also targets the interleukin-5 pathway but binds directly to the receptor on eosinophils.
  • Dupilumab (Dupixent): blocks interleukin-4 and interleukin-13, both involved in type 2 inflammation.
  • Tezepelumab (Tezspire): targets TSLP, an inflammatory signaling molecule that acts further upstream than the others, which is why it can help patients whose asthma isn’t clearly eosinophilic.

Clinical data on these biologics generally show reduced flare-up rates, improved lung function, and better quality of life.7Frontiers in Immunology (Europe PMC). Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives Some monoclonal antibodies that showed early promise, such as tralokinumab and lebrikizumab (both targeting interleukin-13) and secukinumab (targeting interleukin-17A), did not pan out in asthma trials and have been discontinued for that use, though some remain approved for other conditions like eczema.8Frontiers in Immunology (Europe PMC). Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives

Older Drug Names You May Still Encounter

A century ago, asthma treatment looked nothing like it does today. The main options were ephedrine, theophylline tablets, and inhaled anticholinergics delivered through “asthma cigarettes,” along with adrenaline injections for acute attacks.9PubMed. Asthma therapy over 100 years Theophylline, a methylxanthine chemically related to caffeine, is still occasionally prescribed today for difficult-to-control asthma, though its narrow safety margin and frequent side effects have pushed it to the margins. You may also hear about aminophylline, which is simply theophylline combined with a salt to make it more soluble for intravenous use in emergencies.

Selective phosphodiesterase-4 (PDE4) inhibitors represent a newer branch of this older family tree. Roflumilast (Daliresp) is the most prominent PDE4 inhibitor, though it is primarily approved for COPD rather than asthma. Despite sharing some theoretical overlap with theophylline’s mechanism, PDE4 inhibitors have a distinct pharmacological profile and different side-effect patterns.10Europe PMC. Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases

Why Knowing Your Inhaler’s Name Actually Matters

This isn’t just trivia. A study of over 1,100 asthma patients found that about 44% used non-standard names for their inhalers, calling them things like “the purple one” or “my breathing pump” instead of using either the brand or generic name. Those patients had measurably worse outcomes. Compared to patients who correctly identified their inhalers, those using non-standard names had roughly 30% more courses of oral corticosteroid bursts (a sign of worsening asthma), about 43% more emergency department or urgent care visits for asthma, and higher odds of being hospitalized.11The Journal of the American Board of Family Medicine. What Patients Call Their Inhalers Is Associated with “Asthma Attacks”

The association held even after adjusting for other factors. The likely explanation isn’t that knowing a name magically prevents flare-ups but that using non-standard names signals a disconnect with the treatment plan. If you call your controller inhaler “the brown one” and your rescue inhaler “the blue one,” you may be less clear on why you’re taking each and more likely to skip the controller on days you feel fine, or more likely to confuse the two. This is particularly risky when brand manufacturers update their inhaler designs and the colors change.

Color Codes, Labels, and Practical Identification

Speaking of color: there is no universal color-coding standard for inhalers, which is a longstanding complaint among asthma educators. In many countries, rescue SABAs tend to come in blue inhalers and ICS controllers in brown or orange ones, but this convention is not legally mandated and exceptions exist. Some pharmacies have started adding their own labeling to help. In one program, pharmacists applied red stickers labeled “RESCUE” to short-acting beta-agonist inhalers and green stickers labeled “USE EVERY DAY” to corticosteroid or combination ICS/LABA inhalers.12PEC Innovation. Improving asthma self-management education through inhaler labeling

If you use multiple inhalers, a practical step is to write the purpose on each device with a permanent marker or use colored tape, especially if your inhalers are similar colors. The distinction between a daily controller and a rescue inhaler is the single most important thing to keep straight, regardless of what names you use. Getting this wrong, using only the rescue inhaler and skipping the controller, is one of the most common patterns that leads to poorly controlled asthma.

How Drug Name Stems Can Help You Navigate

You don’t need to memorize a pharmacology textbook, but recognizing a few naming patterns can make the whole landscape feel less chaotic. The stem system used in generic drug names was designed to let healthcare professionals quickly identify a drug’s class, and it works for patients too once you know what to look for:

These stems are part of the International Nonproprietary Name (INN) system, and they’re consistent worldwide even when brand names differ between countries. Knowing them gives you a shortcut through the confusion: if a doctor mentions a new medication and the generic name ends in “-terol,” you already know it’s a bronchodilator, even before looking it up.

When the Same Drug Has Different Names in Different Countries

One of the most common sources of confusion is geographic variation. Salbutamol and albuterol are the most famous example, the same molecule with two names because the United States adopted its own naming convention. But the problem extends beyond rescue inhalers. Fluticasone propionate/salmeterol is Advair in the U.S., Seretide in Europe and Australia, and may carry yet another brand name in Asia. Budesonide/formoterol is Symbicort almost everywhere, which is a rare case of global brand consistency.

If you travel internationally or read health information from other countries, the generic name is your anchor. Brand names are marketing decisions that vary by manufacturer and market; the generic name tells you the actual drug. This is especially relevant for biologics: omalizumab is Xolair globally, but as biosimilars (near-copies of biologic drugs) enter the market, each biosimilar gets its own distinct brand name while sharing the same generic root. You may start seeing “omalizumab-xyz” formulations with unfamiliar brand names that contain the same essential molecule.

For practical purposes, keeping a list of your generic drug names, their doses, and which device they come in gives you a reliable record that any healthcare provider anywhere in the world can interpret, regardless of local brand-name conventions. The brand name on the box is the least stable part of a medication’s identity.